Similarly, targeting the interface between MYC and MIZ1 to disrupt the complex that contributes to the downregulation of certain pro‐immunogenic genes is likely to increase immune visibility of tumor cells in vivo [38, 39, 121]. The gene discussed is MYC; the disease is neoplasm.